The global infant formula market is expanding rapidly, driven by rising disposable incomes in Asia-Pacific, premiumisation of products, and growth in specialised and follow-on formulas. According to the data you provided, the market grew from about US$82.4 billion (2024) to US$90.27 billion (2025) and is projected to reach ~US$207.19 billion by 2034, implying a strong mid- to long-term CAGR and sizable category shifts toward premium, baby-food extensions and modern retail distribution. Asia-Pacific led the market in 2024, supermarkets & hypermarkets were the largest distribution channel, while follow-on milk and specialty baby-food segments are among the fastest growing.
Download the free sample and get the full report for complete insights and forecasts on this market @ https://www.towardshealthcare.com/download-sample/5564
◉Quick facts: Global leader in infant & toddler nutrition with major brands such as NAN, Illuma, Nestogen and a large baby-food portfolio under Gerber (Nestlé nutrition division is a major pillar of the company).
◉Strengths:
•Very large global manufacturing & distribution footprint (strong presence across APAC, Europe, Americas).
•Investment in premiumisation and R&D (focus on HMOs, advanced formulations and targeted nutrition for different life stages).
•Wide portfolio spanning value to premium segments — helps capture both mass and affluent consumers.
◉Key products / brands: NAN, Illuma (premium), Nestogen, Gerber baby foods, plus fortified/medical nutrition SKUs.
◉Quick facts: Danone’s Specialized Nutrition arm (including Aptamil, Nutricia) is a top global player in infant formula and baby foods, with especially strong positions in Europe and growing activity in APAC and the U.S. market via exports.
◉Strengths:
•Scientific/medical-nutrition positioning — strong clinical credentials and R&D pipeline for infant formulations.
•Flexible supply chain — Danone has used European production to ship into other regions during supply shortfalls.
•Strong brand equity in Europe (Aptamil/Nutricia) and established baby-food portfolio.
◉Key products / brands: Aptamil, Nutrilon/Nutricia, Bledina (baby food), stage-based formula ranges and specialty medical nutrition lines.
◉Quick facts: Abbott’s Nutrition division sells Similac (flagship infant formula) and a portfolio of specialty and clinical infant feeds; it is a major player in the U.S. and other markets.
◉Strengths:
•Strong clinical/product development capabilities (focus on close-to-breast-milk formulations, HMOs, prebiotics/probiotics).
•Broad product range including standard, specialty, metabolic and high-calorie formulas used in hospitals and by paediatricians.
•Solid regulatory and quality focus with global distribution in retail and healthcare channels.
◉Key products / brands: Similac family (Similac 360 Total Care, Similac with Iron 24, specialty formulas), plus clinical nutrition SKUs for hospitals.
◉Quick facts: Reckitt owns Mead Johnson’s portfolio (including Enfamil, historically one of the top global infant-formula brands). The business has faced litigation and strategic review in recent years; company is evaluating options for the nutrition unit.
◉Strengths:
•Very strong brand recognition for Enfamil (noted as a top recommended brand among U.S. paediatricians) and established specialty allergy products (Nutramigen).
•Deep clinical relationships with healthcare professionals and hospital channels for specialized nutrition.
•Commercial / strategic context (latest):
Reckitt has been conducting a strategic review of Mead Johnson and has signalled possible divestment options while defending product safety amid litigation; this is an active corporate development area that may affect the business’s future structure.
◉Key products / brands: Enfamil, Nutramigen, plus specialized pediatric nutrition products.
◉Quick facts: FrieslandCampina is a major dairy cooperative with Friso / Friso Gold infant-nutrition brands and an ingredients business supplying MFGM, oligosaccharides and other components used by formulators.
◉Strengths:
•Strong dairy sourcing (cooperative model) and ingredient-level capabilities (supplies MFGM, lactoferrin and other speciality ingredients to formulators).
•Regional leadership in parts of Asia (Friso is a recognized premium brand in many APAC markets).
•Continued investment in ingredient approvals and country registrations (supports faster product launches).
◉Key products / brands: Friso / Friso Gold (stage-based formulas), ingredient lines (Vivinal® MFGM, proteins, etc.).
Immediate Delivery Available | Buy This Premium Research @ https://www.towardshealthcare.com/price/5564
Access our exclusive, data-rich dashboard dedicated to the therapeutic area sector – built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.
Access the Dashboard: https://www.towardshealthcare.com/access-dashboard
Become a valued research partner with us – https://www.towardshealthcare.com/schedule-meeting
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
The global ultrasound market is valued at USD 10.1 billion in 2024 and is expected to grow to USD 20.34… Read More
The global natural language processing (NLP) in healthcare and life sciences market is experiencing rapid growth, valued at USD 6.66… Read More
The global nurse call systems market was valued at USD 2.2 billion in 2024 and is expected to grow significantly,… Read More
The bioprocess containers market is in rapid expansion driven by strong adoption of single-use technologies across biopharma manufacturing, rising biologics… Read More
The global ultrasound market is growing from a roughly $10B base in the mid-2020s toward a substantially larger market over… Read More
The NLP in healthcare & life-sciences market is rapidly expanding — several market reports place the industry at roughly USD… Read More